Please assess the completion status of the following clinical trial:

Trial Title: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects, aged \>/= 18 years~* Subjects with histologically or cytologically proven advanced castration-resistant prostate cancer (CRPC)~  * who failed at least 1 taxane regimen and are refractory to abiraterone and/or enzalutamide therapy OR~ * who have actively refused any treatment which would be regarded standard.~* Subjects should have undergone bilateral orchiectomy or should be on continuous androgen deprivation therapy with a gonadotropin releasing hormone agonist or antagonist.~* Subjects must have shown progressive disease after discontinuation of anti-androgen therapy (i.e. flutamide, bicalutamide or nilutamide) before study drug treatment.~* Total serum testosterone should be less than 50 ng/ml or 1.7 nmol/L~* Evidence of progressive disease, defined as one or more (Prostate Cancer Working Group 2 (PCWG2) criteria):~* PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart~* Nodal (in lymph nodes \>/= 2cm) or visceral progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST)~* Appearance of one more new lesions in bone scan~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2~* Life expectancy of at least 3 months~Exclusion Criteria:~* Any anticancer therapy or immunotherapy within 4 weeks of start of first dose~* Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy~* Prior radiotherapy (local palliative radiotherapy is permitted)~* History of allergic reactions to monoclonal antibody therapy~* History of clinical significant cardiac disease: including unstable angina, acute myocardial infarction within 6 months prior to first study treatment, congestive heart failure ≥New York Heart Association (NYHA) Class III), and arrhythmia requiring therapy except for beta-blockers, calcium channel blockers and digoxin or uncontrolled hypertension, despite optimal medical management~* Clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QT interval corrected for heart rate (QTc)-interval over 450 msec~* Current evidence or history of uncured (i.a. any absolute risk of latent infection) of hepatitis B or C or human immunodeficiency virus (HIV) infection~* Chronic systemic corticosteroid therapy or any other immunosuppressive therapies should have been stopped at screening start~* Seizure disorder requiring therapy (such as steroids or anti-epileptics)~* Subjects unable to inject the study drug subcutaneously for intended s.c. application~* Non-suitable for a central venous access for intended c.i.v. administration

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY2010112 (s.c.) (Type: EXPERIMENTAL): None
- BAY2010112 (c.i.v.) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete